A study of microwave ablation for small cell lung cancer

• Published in: Journal of cancer research and therapeutics 2022-04, Vol.18 (2), p.399-404
• Main Authors: Wang, Jiao, Hu, Likuan, Yang, Xia, Ye, Xin, Ni, Yang, Meng, Min, Huang, Guanghui, Zhang, Tiehong, Li, Wenhong, Han, Xiaoying, Wei, Zhigang, Dai, Jianjian, Zou, Zhigeng
• Format: Article
• Language: English
• Subjects: Ablation; Ablation (Surgery); Cancer; Care and treatment; Chemotherapy; Combined modality therapy; Humans; Lung cancer; Lung cancer, Small cell; Lung Neoplasms - radiotherapy; Lung Neoplasms - surgery; Methods; Microwaves - adverse effects; Patient outcomes; Radiofrequency Ablation - adverse effects; Radiotherapy; Retrospective Studies; Small Cell Lung Carcinoma - radiotherapy; Small Cell Lung Carcinoma - surgery
• ISSN: 0973-1482; 1998-4138
• DOI: 10.4103/jcrt.jcrt_1965_21

Purpose: To reveal the survival and safety of percutaneous microwave ablation (MWA) combined with chemoradiotherapy (CRT) in treating small cell lung cancer (SCLC). Materials and Methods: Clinical data of 48 SCLC patients who underwent MWA were retrospectively collected; survival and incidence of major complications were analyzed. Results: Totally, 48 SCLC patients underwent 51 MWA procedures. The median overall survival (OS) for all SCLC was 27.0 months (95% confidence interval 22.4-31.6 months). The OS of limited-stage (LS-SCLC) was longer than the extensive-stage (ES-SCLC) (median 48.0 months vs. 25.0 months, P = 0.022). The OS of SCLC with tumor diameter ≤3.0 cm was longer than that of tumor diameter >3.0 cm (median 48.0 months vs. 27.0 months, P = 0.041). For LS-SCLC, the 1-, 2-, 3-, and 5-year survival rate was 91.67%, 72.22%, 66.67%, and 61.11%, respectively. For ES-SCLC, the 1-, 2-, and 3-year survival rates were 83.33%, 50.0%, and 8.33%. Major complications included pneumothorax needing tube placement (29.4%), rarely arrhythmia (2.0%), empyema (2.0%), pulmonary fungal infection (2.0%), and shingles (2.0%). Conclusion: For SCLC patients, who received MWA combined with CRT, OS of LS-SCLC and tumor diameter ≤3.0 cm was better than that of the ES-SCLC and tumor diameter >3.0 cm. For inoperable SCLC, MWA was safe.